Sei Investments Co. trimmed its holdings in shares of Perrigo Company plc (NYSE:PRGO) by 25.4% during the 4th quarter, HoldingsChannel reports. The fund owned 97,893 shares of the company’s stock after selling 33,391 shares during the period. Sei Investments Co.’s holdings in Perrigo were worth $8,533,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Greenlight Capital Inc. boosted its holdings in shares of Perrigo by 14.8% in the 3rd quarter. Greenlight Capital Inc. now owns 2,901,032 shares of the company’s stock valued at $245,572,000 after buying an additional 374,032 shares in the last quarter. Parnassus Investments CA boosted its holdings in shares of Perrigo by 7.1% in the 3rd quarter. Parnassus Investments CA now owns 2,257,000 shares of the company’s stock valued at $191,055,000 after buying an additional 150,000 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Perrigo by 90.5% in the 4th quarter. Victory Capital Management Inc. now owns 2,046,980 shares of the company’s stock valued at $178,414,000 after buying an additional 972,210 shares in the last quarter. Legal & General Group Plc boosted its holdings in shares of Perrigo by 1.8% in the 3rd quarter. Legal & General Group Plc now owns 674,091 shares of the company’s stock valued at $57,059,000 after buying an additional 12,023 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Perrigo by 40.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 622,690 shares of the company’s stock valued at $52,699,000 after buying an additional 180,348 shares in the last quarter. Institutional investors own 82.44% of the company’s stock.
In other Perrigo news, EVP John Wesolowski purchased 700 shares of Perrigo stock in a transaction on Thursday, December 14th. The stock was bought at an average cost of $85.80 per share, with a total value of $60,060.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Todd W. Kingma sold 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, December 28th. The stock was sold at an average price of $88.52, for a total transaction of $132,780.00. Following the transaction, the vice president now directly owns 19,565 shares of the company’s stock, valued at $1,731,893.80. The disclosure for this sale can be found here. Insiders have sold a total of 3,838 shares of company stock valued at $336,784 over the last three months. 6.90% of the stock is currently owned by insiders.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 20th. Shareholders of record on Friday, March 2nd will be given a dividend of $0.19 per share. The ex-dividend date of this dividend is Thursday, March 1st. This is a positive change from Perrigo’s previous quarterly dividend of $0.16. This represents a $0.76 dividend on an annualized basis and a yield of 0.86%. Perrigo’s dividend payout ratio (DPR) is currently -6.99%.
PRGO has been the topic of a number of recent analyst reports. Cantor Fitzgerald set a $107.00 price target on shares of Perrigo and gave the company a “buy” rating in a report on Friday, December 22nd. Argus upgraded shares of Perrigo from a “hold” rating to a “buy” rating and set a $93.00 price target on the stock in a report on Friday, December 8th. Finally, Canaccord Genuity set a $100.00 price target on shares of Perrigo and gave the company a “buy” rating in a report on Tuesday, December 26th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $93.47.
Perrigo Company Profile
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Want to see what other hedge funds are holding PRGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Perrigo Company plc (NYSE:PRGO).
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.